Brokerages Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Target Price at $18.00

Shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) have been assigned an average rating of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $18.00.

A number of analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Eupraxia Pharmaceuticals in a report on Monday, May 4th. Zacks Research upgraded shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, May 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, July 15th. Wall Street Zen cut Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Oppenheimer initiated coverage on Eupraxia Pharmaceuticals in a research report on Thursday, June 25th. They set an “outperform” rating and a $17.00 target price on the stock.

Eupraxia Pharmaceuticals Trading Down 0.6%

EPRX opened at $6.48 on Monday. The company has a current ratio of 19.31, a quick ratio of 19.31 and a debt-to-equity ratio of 0.02. The firm has a market cap of $421.33 million, a price-to-earnings ratio of -6.17 and a beta of 1.08. Eupraxia Pharmaceuticals has a 12 month low of $5.04 and a 12 month high of $9.32. The stock has a fifty day moving average price of $6.43 and a 200-day moving average price of $7.24.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). As a group, equities research analysts anticipate that Eupraxia Pharmaceuticals will post -0.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Affinity Asset Advisors LLC grew its position in Eupraxia Pharmaceuticals by 429.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock worth $11,504,000 after purchasing an additional 1,289,005 shares during the last quarter. Vivo Capital LLC purchased a new stake in shares of Eupraxia Pharmaceuticals during the third quarter valued at $7,965,000. Seven Fleet Capital Management LP purchased a new stake in shares of Eupraxia Pharmaceuticals during the first quarter valued at $5,137,000. Redmile Group LLC acquired a new position in shares of Eupraxia Pharmaceuticals in the 1st quarter valued at $5,068,000. Finally, Rubric Capital Management LP purchased a new position in Eupraxia Pharmaceuticals in the 1st quarter worth $5,004,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.